pemetrexed + bevacizumab

This combination therapy regimen consists of pemetrexed and bevacizumab, being investigated for the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). Pemetrexed is a small molecule multitargeted antifolate chemotherapy agent that inhibits several enzymes involved in folate metabolism, thereby disrupting the synthesis of nucleotides required for DNA and RNA replication. Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), an essential regulator of angiogenesis, to inhibit the blood supply to tumors. This specific protocol, sponsored by Kobe City General Hospital, focuses on a pemetrexed rechallenge combined with bevacizumab in patients who previously received pemetrexed-containing therapy and did not experience disease progression during that initial treatment.

Other names

pemetrexed and bevacizumabpemetrexed rechallenge with bevacizumabpemetrexed + bevacizumab-Kobe City General Hospital-non-small cell lung cancer (non-squamous)